drugset / Trial / NCT06834230

Effect of Dotinurad in Hyperuricemia With Hypertension

NCT06834230

Phase 4 Recruiting 360 enrolled Saga University
RandomizedParallel-groupOpen-labelTreatment

Summary

The effect of dotinurad on CAVI (cardio-ankle vascular index) will be compared with that of febuxostat in patients with hyperuricemia complicated by hypertension.

Timeline

Start
2025-03-28
Primary completion
2027-07-31
Completion
2030-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dotinurad Small molecule 2 mg
Comparator Febuxostat Small molecule 40 mg